0000830656 false 0000830656 2022-12-29 2022-12-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares





Washington, D.C. 20549










Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): December 29, 2022





(Exact name of registrant as specified in its charter)




Massachusetts   001-38185   04-2652826
(State or Other Jurisdiction   (Commission   (I.R.S. Employer
of Incorporation)   File Number)   Identification No.)


14 Norfolk Avenue

South Easton, MA 02375

(Address of Principal Executive Office) (Zip Code)


(508) 230-1828

(Registrant’s telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company


If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐







Item 5.07 Submission of Matters to a Vote of Security Holders.


On December 29, 2022, Pressure BioSciences, Inc. (the “Company”) held a special meeting in lieu of the annual meeting of stockholders (the “Meeting”). At the Meeting, the stockholders voted on the following proposals described in detail in the Company’s definitive proxy statement for the Meeting filed with the Securities and Exchange Commission on December 6, 2022. As of the record date for the Meeting, there were 11,128,187 shares of the Company’s common stock, par value $0.01 per share, issued and outstanding and entitled to one vote for each share held. The holders of 60.59% of the Company’s shares of common stock outstanding (6,742,402) submitted votes by proxy or in person at the Meeting, constituting a quorum.


Proposal 1 - Elect two directors as Class II Directors until the 2025 Annual Meeting of Stockholders. The election of the directors was approved as follows:


Nominee  For   Against  

Shares voted


   Broker Non-Votes 
Vito J. Mangiardi   4,967,267    N/A    173,000    1,602,135 
Kevin A. Pollack   5,007,054    N/A    133,213    1,602,135 


Proposal 2 - Ratify the appointment of MaloneBailey LLP as the Company’s independent auditor for fiscal year 2022. The ratification of the appointment of MaloneBailey LLP as the Company’s independent auditor for fiscal year 2022 was approved as follows:


   Shares voted 
For   6,600,688 
Against   97,770 
Abstain   43,944 
Broker Non-Votes   0 







Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.


Dated: January 5, 2023 By: /s/ Richard T. Schumacher

Richard T. Schumacher

President and Chief Executive Officer